The new 7.2mg dose produces approximately 20.7% weight loss, essentially matching Mounjaro 15mg, compared to 14.9% at the standard 2.4mg dose.
This medication shares 94% sequence homology with human GLP-1, which makes it remarkably good at binding to and activating GLP-1 receptors throughout our body
However, total weight loss at 12 months is similar between genders when controlling for starting weight
Patients who may benefit from discussing LDN with a Provn provider include: Those with significant needle anxiety that GLP-1 therapy would compound Those with a history of pancreatitis or other GLP-1 contraindications Those with autoimmune conditions who havent responded to conventional weight management approaches Those experiencing chronic inflammation that may contribute to metabolic difficulty Those who have tried GLP-1 therapy without success or with intolerable side effects LDN is taken as a daily oral capsule at bedtime, avoiding the storage, injection, and travel logistics associated with GLP-1 injectable therapy
Supports DMPK, toxicology, and follow-up studies on bioactivation pathways